BioStem Registers 12.05M Shares for $40M Roth Equity Facility — Up to 40% Dilution
BSEM sits 70% above its 52-week low of $2.251.
Summary
BioStem's prospectus activates a $40M committed equity facility with Roth, registering 12.05M shares that could dilute existing holders by roughly 40% — capital needed to address a going-concern warning and a $10M payment obligation.
Key Events · Financing and Capital Events · BSEM
-
$40M Equity Facility Activated
Prospectus dated September 29, 2026 makes effective the September 18, 2026 committed equity facility with Roth Principal Investments, allowing BioStem to sell up to $40M of common stock over 36 months at its discretion.
-
Up to 40.2% Dilution
The 12,050,000 registered shares would represent approximately 40.2% of the 17,935,843 shares outstanding as of September 17, 2026 — a highly dilutive overhang if fully drawn.
-
Exchange Cap Limits Access
Nasdaq rules cap issuance at 3,585,375 shares (19.99% of outstanding) without shareholder approval, unless the average purchase price equals or exceeds $4.3056 — meaning full $40M access may require additional votes or higher stock prices.
-
Going-Concern Context
The facility addresses a going-concern warning and a $10M Catalyze payment obligation that was due September 15, 2026, with cash at $6.96M as of June 30, 2026.
Analysis · BSEM · Life Sciences
The prospectus makes the $40M committed equity facility with Roth Principal Investments effective, allowing BioStem to draw capital at its discretion over 36 months. The 12,050,000 registered shares would represent approximately 40.2% of the 17.9M shares outstanding — a highly dilutive overhang for a company already carrying a going-concern warning and a $10M Catalyze payment obligation that was due September 15, 2026. The facility gives BioStem a lifeline to fund that obligation and operations, but at the cost of selling shares at a 3-5% discount to VWAP, with a $1.00 floor price. The Exchange Cap limits issuance to 3,585,375 shares (19.99%) without shareholder approval unless the average price exceeds $4.3056, meaning full access to the $40M may require additional shareholder votes or higher stock prices.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.2% of the 1581 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $3.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.3M. The 52-week trading range was $2.25 to $8.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.